Deloitte September 3, 2024
What’s on the horizon for the advanced therapy (AT) market? Our survey of advanced therapy developers (ATDs), advanced therapy manufacturing organizations (ATMOs), and health care providers (HCPs) and payers reveals a shared optimism and pinpoints key areas to watch. Explore cell and gene therapy insights that can help steer decision-making in the future of personalized medicine.
Insights from the frontlines of advanced therapy
Dive into the findings from our 2024 state of the advanced therapy industry report, highlighting important trends and insights from 376 industry stakeholders across the cell and gene therapy market. Our survey, expanded this year to capture diverse viewpoints, sheds light on optimism in the industry, growth strategies, and pressing...
Today's Sponsors
Today's Sponsor